Absci to Participate in Upcoming Investor Conferences
- VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
- 08/21/2024
|
Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript
- Absci Corporation (NASDAQ:ABSI ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann - SVP of Drug Creation Conference Call Participants Steven Mah - TD Cowen Srikripa Devarakonda - Truist George Farmer - Scotiabank Scott Schoenhaus - KeyBanc Operator Good day and thank you for standing by. Welcome to the Absci Second Quarter 2024 Business Update Conference Call.
- 08/16/2024
|
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
- Absci Corporation (ABSI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.27 per share a year ago.
- 08/14/2024
|
Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
- Released results from non-human primate studies for ABS-101, demonstrating 2-3x extended half-life as compared to antibodies in clinical development
- 08/14/2024
|
Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
- The collaboration unites Absci's Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics The collaboration unites Absci's Generative AI Drug Creation Platform with leading oncology experts to co-develop up to six novel cancer therapeutics
- 08/12/2024
|
Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
- Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
- 07/28/2024
|
Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024
- VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the second quarter after market close on Wednesday, August 14, 2024.
- 07/10/2024
|
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stock to Ms. Shelby Walker in connection with her employment as Absci's Chief Legal Officer. The inducement grant was previously approved by Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to Ms. Walker's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
- 07/03/2024
|
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.
- 05/28/2024
|
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
- It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?
- 05/16/2024
|
Absci Corporation (ABSI) Q1 2024 Earnings Call Transcript
- Absci Corporation. (NASDAQ:ABSI ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Alex Khan – Vice President, Finance and Investor Relations Sean McClain – Founder and Chief Executive Officer Zach Jonasson – Chief Financial Officer and Chief Business Officer Christian Stegmann – SVP of Drug Creation Conference Call Participants Kripa Devarakonda – Truist Securities George Farmer – Scotia Bank Jacqueline Kisa – TD Cowen Steve Dechert - KeyBanc Capital Markets Li Chen – H.C.
- 05/14/2024
|
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
- Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024.
- 05/14/2024
|
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
- The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.
- 05/07/2024
|
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
- Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 04/10/2024
|
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
- Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering VANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2023.
- 03/21/2024
|
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
- VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $86.4 million. All of the shares in the offering were sold by Absci.
- 03/01/2024
|
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
- Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 03/01/2024
|
Absci Announces Pricing of Public Offering of Common Stock
- VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,505,000 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $75.2 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Absci.
- 02/27/2024
|
Absci Announces Proposed Public Offering of Common Stock
- VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. Absci also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Absci.
- 02/27/2024
|
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
- IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
- 02/21/2024
|
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?
- Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
- 02/05/2024
|
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
- VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets.
- 01/10/2024
|
Absci to Participate in the 26th Annual Needham Growth Conference
- VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming 26th Annual Needham Growth Conference.
- 01/03/2024
|
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
- 12/28/2023
|
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
- Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Active Programs signed for the year VANCOUVER, Wash., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife®, a leading computational biology company driving precision medicine in complex chronic diseases, today announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs.
- 12/20/2023
|
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
- Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
- 12/05/2023
|
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
- Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development
- 12/04/2023
|
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
- Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.
- 12/03/2023
|
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
- VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.
- 11/15/2023
|
Absci to Participate in Upcoming Investor Conferences
- VANCOUVER, Wash. and NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences in New York, NY.
- 10/26/2023
|
Absci to Participate in Upcoming Investor Conferences
- VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
- 08/28/2023
|
The 3 Most Undervalued Penny Stocks to Buy Now: August 2023
- Penny stocks are often defined as stocks trading under $5 per share, those with a very low price per share or market capitalization, and are generally higher-risk. Now, despite many such stocks certainly carrying a relatively high risk profile, this often is somewhat offset by higher potential returns.
- 08/14/2023
|
Beyond OpenAI: 7 promising startups that have saved lives, sped up drug development and improved manufacturing
- OpenAI is stealing the spotlight as the definitive artificial-intelligence startup — for now. Backed by Microsoft Corp. MSFT, the progenitor of ChatGPT-4 has become the focus of the AI wave, but other AI startups are emerging in fields including healthcare, education and manufacturing.
- 06/01/2023
|
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
- Absci Corporation (ABSI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.33 per share a year ago.
- 05/15/2023
|
Absci Takes Its Generative AI Antibody Design Platform To Europe
- Generative AI technology, like ChatGPT, is disrupting many industries including biopharma. For example, Absci is using AI to design & validate de novo antibodies.
- 02/28/2023
|
Publicly traded biotech company Absci lays off employees, citing ‘macro-economic conditions'
- Vancouver, Wash.
- 08/10/2022
|
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
- Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
- 08/09/2022
|
Here's Why Absci Corp Shares Are Falling
- Absci Corp (NASDAQ: ABSI) shares are trading lower by 9.2% at $6.79 after the company reported fourth-quarter earnings results. Absci reported quarterly losses of 28 cents per share.
- 03/23/2022
|
Absci to Present at Global AI Conference NVIDIA GTC
- VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the therapeutic potential of proteins, today announced that Absci Lead AI Scientist Joshua Meier will be presenting at NVIDIA GTC .
- 03/16/2022
|
Is a Surprise Coming for Absci (ABSI) This Earnings Season?
- Absci (ABSI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/11/2022
|
Absci to Participate in Upcoming Investor Conferences
- VANCOUVER, Wash., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the following investor conferences.
- 02/17/2022
|
Absci (ABSI) Inks Research Agreement With Merck, Stock Up
- Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.
- 01/10/2022
|
Absci Corp up 50% after announcing research collaboration with Merck
- Absci Corporation (NASDAQ: ABSI) went up 50% after it announced that it had executed a research and collaboration agreement with Merck, commonly referred to as MSD outside Canada and the US. The company came to this agreement via its AI-powered Integrated Drug Creation Platform.
- 01/07/2022
|
DOGZ Alert: Why Pet Penny Stock Dogness Is Running Higher Today
- Dogness (DOGZ) stock is on a run Friday as investors react to recent volatility surrounding the shares alongside heavy trading. The post DOGZ Alert: Why Pet Penny Stock Dogness Is Running Higher Today appeared first on InvestorPlace.
- 01/07/2022
|
ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today
- Absci (ABSI) stock is flying higher on Friday after announcing a major research collaboration agreement with Merck (MRK). The post ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today appeared first on InvestorPlace.
- 01/07/2022
|
Why Absci Shares Are Soaring Today
- Absci Corp (NASDAQ: ABSI) is trading higher Friday after the company announced a research collaboration with Merck & Co Inc (NYSE: MRK). The collaboration will utilize Absci's AI-powered Integrated Drug Creation Platform.
- 01/07/2022
|
Absci stock rockets after collaboration with Merck could lead to more than $600 million in payments
- Shares of Absci Corp. ABSI, -12.78% skyrocketed 59.1% on heavy volume in premarket trading Friday, after the biotechnology company said it could be eligible to receive up to $610 million in upfront fees and milestone payments from Merck & Co. Inc. MRK, -0.06% as part of a research collaboration agreement. Trading volume ballooned to 9.7 million shares, compared with the full-day average of about 324,800 shares, to make the stock the biggest gainer and most actively traded ahead of the open.
- 01/07/2022
|
Absci Stock (ABSI): Why The Price Surged Today
- The stock price of Absci Corp (NASDAQ: ABSI) increased by over 30% pre-market today. This is why it happened.
- 01/07/2022
|
Absci to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
- VANCOUVER, Washington, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating in the H.C. Wainwright BIOCONNECT Virtual Conference.
- 12/30/2021
|
Absci Corporation (ABSI) CEO Sean McClain on Q3 2021 Results - Earnings Call Transcript
- Absci Corporation (ABSI) CEO Sean McClain on Q3 2021 Results - Earnings Call Transcript
- 11/14/2021
|
Biotech company Absci, which recently went public, cuts ribbon on new HQ in Vancouver, Wash.
- Absci cut the ribbon on its new headquarters in Vancouver, Wash.
- 11/03/2021
|
Absci to Report Third Quarter Financial Results on November 9, 2021
- VANCOUVER, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced it will report financial results for the third quarter 2021 on Tuesday, November 9, 2021. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
- 10/14/2021
|
FMR LLC's Top 5 Buys in September
- FMR LLC, the Boston-based asset management company commonly known as Fidelity, disclosed this month that its top-five trades during September included new buys in Toast Inc. ( TOST , Financial), Graphite Bio Inc. ( GRPH , Financial) and Absci Corp. ( ABSI , Financial), as well as major position boosts in ZoomInfo Technologies Inc. ( ZI , Financial) and Celldex Therapeutics Inc. ( CLDX , Financial).
- 10/12/2021
|
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
- CAMBRIDGE, Mass., & VANCOUVER, Wash.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced a discovery collaboration. The partnership will leverage Absci's Drug Creation™ technology for discovery and
- 10/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Absci Corporation - ABSI
- New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation ("Absci" or the "Company") (NASDAQ: ABSI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Absci and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 09/21/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Absci Corporation - ABSI
- NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation ("Absci" or the "Company") (NASDAQ: ABSI).
- 09/20/2021
|
Absci to Participate in the BofA Securities 2021 Tech Solutions for Drug Discovery Conference
- VANCOUVER, Wash., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BofA Securities 2021 Tech Solutions for Drug Discovery Conference.
- 09/13/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Absci Corporation - ABSI
- NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Absci Corporation ("Absci" or the "Company") (NASDAQ: ABSI).
- 09/09/2021
|
Absci Reports Second Quarter 2021 Financial and Operating Results
- VANCOUVER, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30, 2021.
- 09/07/2021
|
Shares of protein discovery platform Absci pop in market debut
- Absci Corp., a Vancouver company behind a multi-faceted drug development platform, went public on Thursday. It's another sign of snowballing interest in new approaches to drug development – a traditionally risky business.
- 07/22/2021
|
Couchbase and 5 Other Companies Are Going Public. What You Need to Know.
- Couchbase, Ryan Specialty Group, and four other companies are scheduled to list their shares Thursday as the surge of IPOs continues.
- 07/22/2021
|
IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)
- Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public today.
- 07/22/2021
|
Absci Announces Pricing of Initial Public Offering
- VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Absci. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Absci, are expected to be $200.0 million, excluding any exercise of the underwriters' option to purchase additional shares. Absci's common stock is expected to begin trading on the Nasdaq Global Select Market on July 22, 2021, under the ticker symbol “ABSI.” The offering is expected to close on July 26, 2021, subject to the satisfaction of customary closing conditions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
- 07/21/2021
|
AbSci Proposes Terms For $200 Million IPO
- AbSci Proposes Terms For $200 Million IPO
- 07/20/2021
|
